Patients with advanced cervical cancer often face a difficult choice. Their tumors have spread or come back, and standard treatments may not work. This new study looked at a specific approach for people with multiple spots of cancer. The team gave these patients radiation to one area and then added a drug called atezolizumab to help their immune system fight the rest of the disease. Twenty-one patients took part in this trial across several medical centers. They received the radiation treatment followed by the immune therapy every three weeks for up to 23 months. The goal was to see if this combination could slow the cancer down or shrink it.
The results showed promise for some. About 24 percent of patients saw their tumors shrink. More than half had their disease stay stable for a while. The cancer remained controlled in the untreated area for an average of 8.6 months. This means the treatment helped keep the disease from growing quickly in those who responded. Eight patients saw their cancer shrink in the specific spot that did not receive radiation. This suggests the immune therapy worked to fight the disease in other parts of the body.
Safety was a key concern for this group. The treatment was generally well tolerated. Some patients experienced side effects like low white blood cell counts, nausea, or low salt levels in their blood. These issues were manageable and did not lead anyone to stop the treatment early. No serious safety events were reported during the study. While the group was small, the findings offer a potential new path for patients who have limited options.
